Bayer MMP Oncologic Enters Phase III Program For Four Solid-Tumor Cancers
Bayer's matrix metalloproteinase inhibitor BAY 12-9566 has entered Phase III comparative trials in four different cancer types.
Bayer's matrix metalloproteinase inhibitor BAY 12-9566 has entered Phase III comparative trials in four different cancer types.